Compare PDFS & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDFS | OPK |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 921.2M |
| IPO Year | 2000 | 2011 |
| Metric | PDFS | OPK |
|---|---|---|
| Price | $34.54 | $1.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $33.67 | $2.03 |
| AVG Volume (30 Days) | 293.0K | ★ 2.4M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | $22.13 | N/A |
| Revenue Next Year | $18.92 | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.91 | $1.10 |
| 52 Week High | $36.99 | $1.60 |
| Indicator | PDFS | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 46.15 |
| Support Level | $30.72 | $1.12 |
| Resistance Level | $35.09 | $1.27 |
| Average True Range (ATR) | 1.77 | 0.04 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 82.76 | 40.00 |
PDF Solutions Inc provides products and services designed to empower organizations across the semiconductor and electronics ecosystem to connect, collect, manage, and analyze data about design, equipment, manufacturing, and test to improve the yield and quality of their products and operational efficiency. The Company's products, services, and solutions include proprietary software, physical intellectual property (IP) for integrated circuit (IC) designs, electrical measurement hardware tools, methodologies, and professional services.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.